In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …

Background Among patients with resectable early-stage non–small-cell lung cancer
(NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune …

Background Approximately 20% of patients with non–small-cell lung cancer (NSCLC)
receive a diagnosis of stage III disease. There is no current consensus regarding the most …

Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …

Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …

Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …

Background Standard treatment with neoadjuvant nivolumab plus chemotherapy
significantly improves outcomes in patients with resectable non–small-cell lung cancer …